Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial.

MLA

Zimmer, Lisa, et al. “Encorafenib, Binimetinib plus Pembrolizumab Triplet Therapy in Patients with Advanced BRAFV600 Mutant Melanoma: Safety and Tolerability Results from the Phase I IMMU-TARGET Trial.” European Journal of Cancer, vol. 158, Nov. 2021, pp. 72–84. EBSCOhost, https://doi.org/10.1016/j.ejca.2021.09.011.

APA

Zimmer, L., Livingstone, E., Krackhardt, A., Schultz, E. S., Göppner, D., Assaf, C., Trebing, D., Stelter, K., Windemuth-Kieselbach, C., Ugurel, S., & Schadendorf, D. (2021). Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial. European Journal of Cancer, 158, 72–84. https://doi.org/10.1016/j.ejca.2021.09.011

Chicago

Zimmer, Lisa, Elisabeth Livingstone, Angela Krackhardt, Erwin S. Schultz, Daniela Göppner, Chalid Assaf, Dietrich Trebing, et al. 2021. “Encorafenib, Binimetinib plus Pembrolizumab Triplet Therapy in Patients with Advanced BRAFV600 Mutant Melanoma: Safety and Tolerability Results from the Phase I IMMU-TARGET Trial.” European Journal of Cancer 158 (November): 72–84. doi:10.1016/j.ejca.2021.09.011.